| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNRIP1 |
| Uniprot No | Q96F85 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-164aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMGDLPGLVRLSIALRIQPNDGPVFYKV DGQRFGQNRTIKLLTGSSYKVEVKIKPSTLQVENISIGGVLVPLELKSKE PDGDRVVYTGTYDTEGVTPTKSGERQPIQITMPFTDIGTFETVWQVKFYN YHKRDHCQWGSPFSVIEYECKPNETRSLMWVNKESFL |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and functional characterization of recombinant CNRIP1 in mammalian cells"**
- **作者**: Zhang et al.
- **摘要**: 本研究成功在HEK293细胞中表达并纯化CNRIP1重组蛋白，验证其与大麻素受体CB1的相互作用，并证明其通过调控cAMP信号通路抑制受体活性，为研究CNRIP1的生理功能提供工具。
2. **"CNRIP1 recombinant protein enhances glucose-stimulated insulin secretion in pancreatic β-cells"**
- **作者**: Johnson et al.
- **摘要**: 通过原核系统表达CNRIP1重组蛋白，发现其通过调节钙离子通道促进β细胞胰岛素分泌，提示其在糖尿病治疗中的潜在应用价值。
3. **"Structural insights into CNRIP1 via recombinant protein crystallization and X-ray analysis"**
- **作者**: Lee et al.
- **摘要**: 利用大肠杆菌表达CNRIP1重组蛋白并进行晶体结构解析，揭示其与大麻素受体结合的关键结构域，为靶向药物设计提供依据。
4. **"CNRIP1 recombinant protein suppresses tumor growth by modulating Wnt/β-catenin signaling"**
- **作者**: Wang et al.
- **摘要**: 在哺乳动物细胞中制备CNRIP1重组蛋白，发现其通过抑制Wnt通路抑制结直肠癌细胞增殖，为癌症治疗研究提供新方向。
(注：以上文献信息为模拟示例，实际文献需通过学术数据库查询。)
**Background of CNRIP1 Recombinant Protein**
CNRIP1 (Cannabinoid Receptor Interacting Protein 1), also known as CRIP1a, is an endogenous regulatory protein that interacts with cannabinoid receptors, particularly CB1 receptors, which are central to endocannabinoid signaling. This pathway modulates diverse physiological processes, including neurotransmission, pain perception, appetite regulation, and metabolic homeostasis. CNRIP1 is expressed in the brain, pancreas, and adipose tissues, suggesting roles in both neurological and metabolic functions.
The recombinant CNRIP1 protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian cell systems*.* Its production enables detailed study of its structure-function relationship, particularly its ability to influence CB1 receptor activity by modulating receptor trafficking, G-protein coupling, or downstream signaling. Recombinant CNRIP1 retains key functional domains, such as the N-terminal region critical for CB1 interaction, and is often purified via affinity tags (e.g., His-tag) for high purity and consistency.
Research applications include elucidating CNRIP1's role in diseases linked to endocannabinoid dysregulation, such as obesity, diabetes, and neurological disorders. It also serves as a tool for drug discovery, aiding in screening compounds that target CB1-CNRIP1 interactions to refine therapeutic strategies with reduced side effects compared to direct CB1 agonists/antagonists. Additionally, recombinant CNRIP1 supports antibody development and mechanistic studies in cellular or animal models, advancing understanding of its regulatory impact on cannabinoid signaling pathways.
Overall, CNRIP1 recombinant protein is a vital resource for exploring endocannabinoid biology and its therapeutic potential.
×
